EARN25

2 Biotech Stocks Options Traders Are Watching

BridgeBio and Esperion Therapeutics both provided drug updates today

Deputy Editor
Mar 6, 2023 at 1:36 PM
facebook X logo linkedin


At least two biotech stocks are seeing increased scrutiny in the options pits, with BridgeBio Pharma Inc (NASDAQ:BBIO) and Esperion Therapeutics Inc (NASDAQ:ESPR) moving in opposite directions following their respective drug updates. 

BridgeBio Stock Hits 12-Month High

Last seen up 61.3% to trade at $17.53 and earlier touching a more than one-year high of $19.39, BridgeBio stock is set to lock in its best-ever session, following positive results from the company's dwarfism therapy. Specifically, BridgeBio's infigratinib -- a potential treatment for a form of dwarfism called achondroplasia -- resulted in an increase of 3.03 centimeters per year. 

Options traders seem to be excited about the news. In fact, 9,020 calls and 4,979 puts have crossed the tape so far today, which is 22 times the intraday average volume. The most popular contract is the March 20 call, followed by the 55 put in the same series, with new positions being opened at both.

Esperion Therapeutics Cholesterol Drug Fails to Impress

Esperion Therapeutics stock, meanwhile, is 21.1% lower to trade at $5.01 at last check, after data from a study of the company's cholesterol-lowering drug, Nexletol, failed to wow investors. Digging deeper, questions arose about Nexletol's ability to reduce the risk of heart attacks and other cardiovascular problems for individuals that can't tolerate statins, as well as worries over the drug's potential to increase sales.

The stock's normally quiet options pits are popping with activity as well, with the 7,948 calls and 2,817 puts that have been traded so far today accounting for four times the amount typically seen at this point. The most popular contract by far is the March 5 put, while new positions are being opened at the 5 call from the same monthly series.

 

You Don’t Need 25 Alerts -- You Need ONE You Can Trust!

That’s the idea behind Trade of the Week, Schaeffer’s newest trade alert.

Every Monday morning before the opening bell, you’ll receive a single, expertly researched trade recommendation -- built from the same proprietary research we’ve been using for over four decades.

It’s not just a signal.

It’s a plan designed for traders who are tired of jumping from alert to alert without ever finding their edge.

No juggling alerts. No switching directions mid-week. Just one clear, expertly researched trade idea -- delivered before the market even opens.

👉 JOIN RIGHT NOW FOR JUST $1 TO GET THE NEXT TRADE!